Drug Profile

VXA-CoV2-1.1-S

Alternative Names: S only COVID-19 vaccine; S-only Wuhan vaccine - Vaxart

Latest Information Update: 27 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaxart
Class COVID-19 vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase II COVID 2019 infections

Most Recent Events

15 May 2025 Biomedical Advanced Research and Development Authority approves a phase IIb trial in COVID-2019 infections
25 Apr 2025 Vaxart terminates the phase II trial in COVID-19 infections (Prevention) in USA as the study drug was no longer available (NCT05067933)
21 Feb 2025 Vaxart received an order from Advanced Technology International on the COVID-19 phase IIb trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com